Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Friday or Monday next opportunity for me
Buy a Bigger Safe
I dont have as many shares as you do, LOL
10x in 23 Months
FDA Shortages:
FDA shortage link for Adderall
https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet&st=c&tab=tabs-1
FDA shortage link for Vyvance
https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Lisdexamfetamine%20Dimesylate%20Capsule&st=c
FDA shortage link for Concerta
https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Methylphenidate%20Hydrochloride%20Tablet,%20Extended%20Release&st=c
FDA shortage link for Naltrexone
https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Naltrexone%20Hydrochloride%20Tablet&st=c
Bullish
BULLISH
Are people still investing in this junk?
$10 Billion dollar combined IMS markets
X 1. Cash Flow Positive Status - 5 years
X 2. Purchase building housing their cGMP registered facility for research, development, manufacturing and packaging of pharmaceutical products.
X 3. Adderall IR $335 Million Approved and Launched
X 4. Adderall XR $1.56 Billion Approved and Launched
X 5. Double digit quarterly revenues in millions
X 6. In house marketing and distribution: Kirko Kirkov, Doug Plassche and their teams
X 7. Prasco/Burel Adderall agreement starting January 1st 2024
X 8. First shipment Adderall XR to PRASCO Dec 2023
X 9. DEA increases manufacturing quotas for Adderall & Vyvance
X 10. Generic Vyvanse - $5.1 BILLION - FDA submission Dec 2023
X 11. FDA Acceptance of Generic OxyContin Sept 2023
__12. Dopamine Agonist (probably Requip XL or Mirapex ER). $12 Million
__13. Undisclosed Antimetabolite ANDA- $42 Million
__14. $50 million in yearly revenues
__15. Generate revenues over $20 million/quarter
__16. Generic OxyContin Approval - FIRST TO FILE Aug 17, 2023 $720 Million
__17. Prevail over Purdue in Generic OxyContin infringement suit - 6 month stay
X 18. Lease additional manufacturing space and storage vault for new Needle Mover ANDAs - Jan 2024
__19. European distribution - Dexcel partnership approval by Israeli Health
__20. Full ownership of Adderall IR $ 335 Million
__21. Full ownership of Adderall XR $ 1.56 Billion
__22. Generic Concerta- $1.2 BILLION FDA submission
__23. Vigabatrin - VigPoder approved Pyros $233 Million trade mark challenge
__24. $100 million in yearly revenues
__25. Patented Unique ADF (w/o naltrexone)-- NDA
__26. Mikah ANDA (s)
__27. Undisclosed ANDAs/NDAs
__28. Antimetabolite ANDA- Methotrexate -$600 Million - unconfirmed
__29. Generic Vyvanse Approval
__30. DollarLand PPS
__31. Uplist to the NASDAQ Exchange
__32. ELTP Elite Pharmaceutical Buyout - less than 2 1/2 years from Feb 2024
__33. Vegas Baby !!!!!!!
PE ratio: 7
Anytime before THE Buyout works for me.
GLTY
Locked $$ Loaded
ELTP
I have more funds coming for end of week or Monday.
GLTY
Shortages:
FDA shortage link for Adderall
https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet&st=c&tab=tabs-1
FDA shortage link for Vyvance
https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Lisdexamfetamine%20Dimesylate%20Capsule&st=c
FDA shortage link for Concerta
https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Methylphenidate%20Hydrochloride%20Tablet,%20Extended%20Release&st=c
FDA shortage link for Naltrexone
https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Naltrexone%20Hydrochloride%20Tablet&st=c
FDA shortage link for Vyvance
https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Lisdexamfetamine%20Dimesylate%20Capsule&st=c
FDA shortage link for Concerta
https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Methylphenidate%20Hydrochloride%20Tablet,%20Extended%20Release&st=c
Elite has four ANDAs, ALL filed and under FDA review:
1. antimetabolite ANDA used to treat inflammatory arthritis.
2. dopamine agonistANDA for the treatment of Parkinson's.
3. ANDA for treatment of pain management .
4. CNS stimulus ANDA used for attention deficit disorder.
Do a link for vyvance: lisdexamfetamine
Extreme Shortage !!
What’s the earliest we can get approval ?
Where are the Bashers? Must be something Huge coming this week ?
ELTP
Vyvance fast track approval !
Thanks for sharing
Very interesting
Seat Belts On !!!
X 1. Cash Flow Positive Status - 5 years
X 2. Purchase building housing their cGMP registered facility for research, development, manufacturing and packaging of pharmaceutical products.
X 3. Adderall IR $335 Million Approved and Launched
X 4. Adderall XR $1.56 Billion Approved and Launched
X 5. Double digit quarterly revenues in millions
X 6. In house marketing and distribution: Kirko Kirkov, Doug Plassche and their teams
X 7. Prasco/Burel Adderall agreement starting January 1st 2024
X 8. First shipment Adderall XR to PRASCO Dec 2023
X 9. DEA increases manufacturing quotas for Adderall & Vyvance
X 10. Generic Vyvanse - $5.1 BILLION - FDA submission Dec 2023
X 11. FDA Acceptance of Generic OxyContin Sept 2023
__12. Dopamine Agonist (probably Requip XL or Mirapex ER). $12 Million
__13. Undisclosed Antimetabolite ANDA- $42 Million
__14. $50 million in yearly revenues
__15. Generate revenues over $20 million/quarter
__16. Generic OxyContin Approval - FIRST TO FILE Aug 17, 2023 $720 Million
__17. Prevail over Purdue in Generic OxyContin infringement suit - 6 month stay
X 18. Lease additional manufacturing space and storage vault for new Needle Mover ANDAs - Jan 2024
__19. European distribution - Dexcel partnership approval by Israeli Health
__20. Full ownership of Adderall IR $ 335 Million
__21. Full ownership of Adderall XR $ 1.56 Billion
__22. Generic Concerta- $1.2 BILLION FDA submission
__23. Vigabatrin - VigPoder approved Pyros $233 Million trade mark challenge
__24. $100 million in yearly revenues
__25. Patented Unique ADF (w/o naltrexone)-- NDA
__26. Mikah ANDA (s)
__27. Undisclosed ANDAs/NDAs
__28. Antimetabolite ANDA- Methotrexate -$600 Million - unconfirmed
__29. Generic Vyvanse Approval
__30. DollarLand PPS
__31. Uplist to the NASDAQ Exchange
__32. ELTP Elite Pharmaceutical Buyout - less than 2 1/2 years from Feb 2024
__33. Vegas Baby !!!!!!!
See ya in 10 years on another MB
Dont forget to renew your subscription.
Couch says Hi !!
$$$$$$$$$$$$$$
See #11.
Keep practicing.
We have 11 1/2 months to top off. Then after that you have to pay Short Term Capital gains up until The Buy Out.
HAMMERTIME !!!!!!!
X 1. Cash Flow Positive Status - 5 years
X 2. Purchase main building housing their cGMP registered facility for research, development, manufacturing and packaging of pharmaceutical products.
X 3. Adderall IR $335 Million Approved and Launched
X 4. Adderall XR $1.56 Billion Approved and Launched
X 5. Double digit quarterly revenues in millions
X 6. In house marketing and distribution: Kirko Kirkov, Doug Plassche and their teams
X 7. Prasco/Burel Adderall agreement starting January 1st 2024
X 8. First shipment Adderall XR to PRASCO Dec 2023
X 9. DEA increases manufacturing quotas for Adderall & Vyvance
X 10. Generic Vyvanse - $5.1 BILLION - FDA submission Dec 2023
X 11. FDA Acceptance of Generic OxyContin Sept 2023
__12. $50 million in yearly revenues
__13. Generate revenues over $20 million/quarter
__14. Generic OxyContin Approval -;FIRST TO FILE Aug 17, 2023 $720 Million
__15. Prevail over Purdue in Generic OxyContin infringement suit - 6 month stay
X 16. Lease additional manufacturing space and storage vault for new Needle Mover ANDAs Jan 2024
__17. European distribution - Dexcel partnership approval by Israeli Health
__18. Full ownership of Adderall IR $ 335 Million
__19. Full ownership of Adderall XR $ 1.56 Billion
__20. Generic Concerta-$1.2 BILLION FDA submission
__21. Vigabatrin - VigPoder approved Pyros $233 Million trade mark challenge
__22. $100 million in yearly revenues
__23. Dopamine Agonist (probably Requip XL or Mirapex ER). $12 Million
__24. Patented Unique ADF (w/o naltrexone)-- NDA
__25. Mikah ANDA (s)
__26. Undisclosed ANDAs/NDAs
__27. Antimetabolite ANDA- Methotrexate -$600 Million - unconfirmed
__28. Undisclosed Antimetabolite ANDA- $42 Million
__29. Generic Vyvanse Approval
__30. DollarLand PPS
__31. Uplist to the NASDAQ Exchange
__32. ELTP Elite Pharmaceutical Buyout - approx 23 months
__33. Vegas Baby !!!!!!!
BULLISH ELTP
My funds are getting here today
Lets Rock !!!!!!!!!!!!!!!!!
I would like to take 400K all or nothing buy
10X if you can make 23 months
I think your on the NASDAQ exchange and dont know it.
I will check the Ihub Hot list to see if thats true .
Locked & Loaded for The Buy Out
Words to live by
GLTY
That gets us to the NASDAQ
Congrats getting in at the HammerBottom.
BuyOUt will be here before we know it
Elite stopped diluting since achieving Cash Flow Positive status
Not many like this on the OTC
If you find another let me know.
Looking at a $50 + million dollar year
Enjoy the ride to BuyOut in 23 months
ELTP
I filled that gap pre market sorry
I have funds coming tomorrow .
I will buy tomorrow whether its 0.13 or 0.16
$1.333
Three Monsters
1.) Concerta,
2.) Vyvanse,
3.) Generic OxyContin, 100% owned by Elite
Bullish
What on the list is a concern ?
X 1. Cash Flow Positive Status - 5 years
X 2. Purchase main building housing their cGMP registered facility for research, development, manufacturing and packaging of pharmaceutical products.
X 3. Adderall IR $335 Million Approved and Launched
X 4. Adderall XR $1.56 Billion Approved and Launched
X 5. Double digit quarterly revenues in millions
X 6. In house marketing and distribution: Kirko Kirkov, Doug Plassche and their teams
X 7. Prasco/Burel Adderall agreement starting January 1st 2024
X 8. First shipment Adderall XR to PRASCO Dec 2023
X 9. DEA increases manufacturing quotas for Adderall & Vyvance
X 10. Generic Vyvanse - $5.1 BILLION - FDA submission Dec 2023
X 11. FDA Acceptance of Generic OxyContin Sept 2023
__12. $50 million in yearly revenues
__13. Generate revenues over $20 million/quarter
__14. Generic OxyContin Approval -;FIRST TO FILE Aug 17, 2023 $720 Million
__15. Prevail over Purdue in Generic OxyContin infringement suit - 6 month stay
X 16. Lease additional manufacturing space and storage vault for new Needle Mover ANDAs Jan 2024
__17. European distribution - Dexcel partnership approval by Israeli Health
__18. Full ownership of Adderall IR $ 335 Million
__19. Full ownership of Adderall XR $ 1.56 Billion
__20. Generic Concerta-$1.2 BILLION FDA submission
__21. Vigabatrin - VigPoder approved Pyros $233 Million trade mark challenge
__22. $100 million in yearly revenues
__23. Dopamine Agonist (probably Requip XL or Mirapex ER). $12 Million
__24. Patented Unique ADF (w/o naltrexone)-- NDA
__25. Mikah ANDA (s)
__26. Undisclosed ANDAs/NDAs
__27. Antimetabolite ANDA- Methotrexate -$600 Million - unconfirmed
__28. Undisclosed Antimetabolite ANDA- $42 Million
__29. Generic Vyvanse Approval
__30. DollarLand PPS
__31. Uplist to the NASDAQ Exchange
__32. ELTP Elite Pharmaceutical Buyout - approx 23 months
__33. Vegas Baby !!!!!!!
About 1 year? Check my old posts.
Some where around the HammerBottom @2¢
Let’s check off 2-4 this quarter Bro.
Locked$Loaded
Huuuuuge week or two coming up !
X 1. Cash Flow Positive Status - 5 years
X 2. Purchase main building housing their cGMP registered facility for research, development, manufacturing and packaging of pharmaceutical products.
X 3. Adderall IR $335 Million Approved and Launched
X 4. Adderall XR $1.56 Billion Approved and Launched
X 5. Double digit quarterly revenues in millions
X 6. In house marketing and distribution: Kirko Kirkov, Doug Plassche and their teams
X 7. Prasco/Burel Adderall agreement starting January 1st 2024
X 8. First shipment Adderall XR to PRASCO Dec 2023
X 9. DEA increases manufacturing quotas for Adderall & Vyvance
X 10. Generic Vyvanse - $5.1 BILLION - FDA submission Dec 2023
X 11. FDA Acceptance of Generic OxyContin Sept 2023
__12. $50 million in yearly revenues
__13. Generate revenues over $20 million/quarter
__14. Generic OxyContin Approval -;FIRST TO FILE Aug 17, 2023 $720 Million
__15. Prevail over Purdue in Generic OxyContin infringement suit - 6 month stay
X 16. Lease additional manufacturing space and storage vault for new Needle Mover ANDAs Jan 2024
__17. European distribution - Dexcel partnership approval by Israeli Health
__18. Full ownership of Adderall IR $ 335 Million
__19. Full ownership of Adderall XR $ 1.56 Billion
__20. Generic Concerta-$1.2 BILLION FDA submission
__21. Vigabatrin - VigPoder approved Pyros $233 Million trade mark challenge
__22. $100 million in yearly revenues
__23. Dopamine Agonist (probably Requip XL or Mirapex ER). $12 Million
__24. Patented Unique ADF (w/o naltrexone)-- NDA
__25. Mikah ANDA (s)
__26. Undisclosed ANDAs/NDAs
__27. Antimetabolite ANDA- Methotrexate -$600 Million - unconfirmed
__28. Undisclosed Antimetabolite ANDA- $42 Million
__29. Generic Vyvanse Approval
__30. DollarLand PPS
__31. Uplist to the NASDAQ Exchange
__32. ELTP Elite Pharmaceutical Buyout - approx 23 months
__33. Vegas Baby !!!!!!!
Was the boiler room open this weekend?
Sorry you waisted your time to come in for that.
Is your village going to do a goat festival this weekend ?